Jonathan Andrus, Chief Business Officer, Clinical Ink
With COVID-19, the value of virtual trials with direct data capture (DDC) is obvious. Bring-your-own-device (BYOD) electronic patient-reported outcome (ePRO) solutions increase adherence while precluding the transfer of devices among patients. This white paper covers a Phase … Read More »
Dan Chichester, Chief Experience Officer, Ogilvy Health
Amy Graham, Client Engagement Officer, Ogilvy Health
Ritesh Patel, Chief Digital Officer – Health, Ogilvy Health
Joe Youssef, Associate Director, Engagement Strategy, Ogilvy Health
For our 2020 Year in Preview issue, we asked 20 provocative questions covering a range of topics from molecule to market. We wanted to push the envelope to understand how the industry’s influencers think about aspirational goals in terms of health, what needs to happen to ad … Read More »
Mohammad Yaghoubi, M.D., Chief Medical Officer at 81qd
Wes Michael, President and Founder of Rare Patient Voice
In this episode, Mohammad Yaghoubi, M.D., Chief Medical Officer at 81qd sits down with Wes Michael, President and Founder of Rare Patient Voice. They discuss the role of AI to support diagnosis and other issues related to improved patient care. Read the related white paper o … Read More »
Dr. Janine Collins, Executive Director, Safety, Epidemiology, Registries and Risk Management
In this podcast, UBC’s Dr. Janine Collins, speaks to the importance of risk management plans and key considerations and benefits of partnering to develop and implement a global risk management plan.
Eli Phillips Jr, PharmD, JD, Vice President, Insights & Engagement and Regulatory Sciences, Cardinal Health
The field of medicine is becoming increasingly precise with new advanced therapies that target disease at a cellular level and healthcare providers who are becoming “micro-specialists” in their fields. As care becomes more precise, so must the efforts to commercialize new dr … Read More »
Andrew Schirmer, CEO, Ogilvy Health
Andrew Schirmer discusses a grander plan for healthcare agencies as the industry evolves.
Bonnie Overton, Group Associate Creative Director, MicroMass Communications
In this episode, we talk about how behavioral science is addressing some of pharma’s biggest challenges.
Anita Nelsen, Vice President, Translational Medicine, Parexel
Angela Qu, Senior Director, Biomarkers & Genomic Medicine, Parexel
The process of drug development is not on a sustainable path forward. The system is inefficient, lengthy and costly. Despite the rising costs of R&D, failure rates are as high as 90% and the average time to market now takes approximately 12 years. Companies are hard pres … Read More »
Chen Admati, Head of Intel Pharma Analytics Platform, Intel Corporation
Marie McCarthy, Senior Director of Product Innovation, Information Technology, ICON
In this episode, Chen Admati and Marie McCarthy talk about utilizing emerging technologies to improve the efficiency of research and development in the pharmaceutical industry.
Michelle Hoiseth, Chief Data Officer, Parexel
Leanne Larson, Corporate Vice President and WW Head, Real-World Evidence, Parexel
The process of drug development is not on a sustainable path forward and needs to shift in order to support patient needs. The system is inefficient, lengthy and costly. Despite the rising costs of R&D, failure rates are as high as 90% and the average time to market now … Read More »
Trina Stonner, President, Avant Healthcare
In this episode, Trina Stonner, President at Avant Healthcare discusses the evolving role of KOLs and their engagements with HCPs. There is also a companion white paper entitled “Being Engaging when Engaging KOLs,” which you can download uning the link below.
Van Zyl Engelbrecht, Clinical Project Director EU, UBC
In this episode, we talk about the history of Orphan Drug legislation, recent legislation and its effects on clinical research, effective clinical trial design for orphan drug trials, key elements of successful commercialization of orphan drugs, and more.
Martin Roessner, MS, Corporate Vice President, Biostatistics, PAREXEL
Greg Cable, Senior Director, GDO Biostatistics, Global Head Biostatistics for Observational Research, PAREXEL
Many experts agree that the current state of pharmaceutical drug development is not on a sustainable path forward. The average drug-to-market time has stagnated at 12-years, R&D costs continue to rise, and failure rates are as high as 90%. To better understand these tren … Read More »
Todd Wright, Senior Vice President, Avant Healthcare
Chris Ryan, Group Creative Director, Avant Healthcare
In this episode, Todd Wright and Chris Ryan discuss the science behind medical storytelling and how the agency works with clients to make the data memorable. It’s quite common for human brains to search for story in everything. Avant Healthcare puts this basic truth into pra … Read More »
Ian Spatz JD, MPA, Senior Advisor, Manatt Health
On October 15, the Trump Administration’s Center for Medicare and Medicaid Services, CMS, published a proposed rule that, if finalized, would require prescription drug makers to include prescription drug price information in broadcast advertising. The Administration stated t … Read More »
Laura Moore, Ed.D, CHES, Lead Health Psychology Specialist, Atlantis Healthcare
Dr. Laura Moore discusses the concept of “chronic cancer,” and the changing treatment landscape. She talks about the challenges in supporting people as they adjust to a cancer diagnosis and engage in self-management of their illness, including treatment adherence. She explai … Read More »
Kevin Kissling, VP, Third Party Logistics, RxCrossroads by McKesson
In this episode, we discuss the timing for planning your commercial strategy, key items in selecting a distribution partner, the most beneficial value-added services in a logistics plan, and business growth beyond the product launch.
Sy Pretorius, MD, Chief Medical & Scientific Officer, PAREXEL
Alberto Grignolo, PhD, Corporate Vice President, PAREXEL
The Innovation Imperative: The Future of Drug Development, is a recent data-driven report developed and released by The Economist Intelligence Unit and commissioned by PAREXEL. The report examines drug development today and evaluates innovations that can accelerate clinical … Read More »